Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2020
Sick of high drug prices, insurers join hospitals to make their own generic medications
23 January 2020 - Everyone complains about high drug prices. But hospitals — and now insurers — are trying to ...
Posted by Michael Wonder on 16 Jan 2020
Cimzia (certolizumab pegol) now approved in Canada for the treatment of non-radiographic axial spondyloarthritis
15 January 2020 - UCB Canada announced today that Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults ...
Posted by Michael Wonder on 16 Jan 2020
Janssen seeks expanded use of Spravato (esketamine) nasal spray in Europe as a treatment for depressive symptoms in adults with major depressive disorder who have current suicidal ideation with intent
15 January 2020 - In two pivotal Phase 3 trials, Spravato combined with comprehensive standard of care achieved statistically significant ...
Posted by Michael Wonder on 15 Jan 2020
Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations
14 January 2020 - HTA recommendations vary widely throughout Europe, even for the same medicine. ...
Posted by Michael Wonder on 15 Jan 2020
Thousands to benefit as PHARMAC set to fund better diabetes drugs
15 January 2020 - Better diabetes drugs are set to be publicly funded - a breakthrough that will help keep ...
Posted by Michael Wonder on 15 Jan 2020
Clovis Oncology’s Rubraca (rucaparib) granted FDA priority review for advanced prostate cancer
15 January 2020 - FDA has assigned PDUFA date of 15 May 2020. ...
Posted by Michael Wonder on 15 Jan 2020
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
15 January 2020 - Cost-effectiveness watchdog issues a round of draft and final guidance. ...
Posted by Michael Wonder on 15 Jan 2020
U.S. FDA accepts for priority review Bristol-Myers Squibb’s application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
15 January 2020 - Application based on results from Part 1 of Phase 3 CheckMate-227 study. ...
Posted by Michael Wonder on 15 Jan 2020
Reform at the FDA—in need of reform
14 January 2020 - On 23 December 2016, the US FDA announced the approval of nusinersen, the first drug for the ...
Posted by Michael Wonder on 15 Jan 2020
Democrats zero in on high drug prices in Iowa debate
14 January 2020 - Until Tuesday, nearly every single Democratic primary debate has focused on the same health care issue: ...
Posted by Michael Wonder on 15 Jan 2020
NICE rejects Keytruda, asks for more information
15 January 2020 - NICE has published a new draft guidance not recommending MSD’s cancer blockbuster Keytruda (pembrolizumab) for untreated ...
Posted by Michael Wonder on 15 Jan 2020
FDA approval and regulation of pharmaceuticals, 1983-2018
14 January 2020 - How has the regulation of prescription drugs evolved from the 1980s to 2018, and what trends have ...
Posted by Michael Wonder on 15 Jan 2020
PHARMAC considering new medicines for type 2 diabetes mellitus
15 January 2020 - PHARMAC is seeking proposals from pharmaceutical suppliers for new medicines that could help New Zealanders living ...
Posted by Michael Wonder on 15 Jan 2020
TLV has decided to reconsider the subsidy for Xeljanz
14 January 2020 - When TLV decided that Xeljanz should be included in the high-cost protection, this was justified by the ...
Posted by Michael Wonder on 15 Jan 2020
Proposal to fund betamethasone dipropionate with calcipotriol (Enstilar) foam spray for psoriasis
15 January 2020 - PHARMAC is seeking feedback on a proposal to fund a new topical psoriasis medicine, betamethasone dipropionate ...
Posted by Michael Wonder on 15 Jan 2020
Amazon Australia signals pharmacy foray with new trademark application
14 January 2020 - The local arm of retail giant Amazon has filed a trademark for the term "Amazon Pharmacy", ...